KardioStatus is a biotechnology software development company founded in 2022 at the Warren Alpert Medical School. Their innovative use of AI technology allows them to analyze patient biometrics and predict individual medical outcomes. The company was created by Anthony Chu, a clinical assistant professor of medicine and cardiac electrophysiologist, along with Anshul Parulkar, a cardiology fellow at Rhode Island Hospital. Together with a team of Brown community members, including medical student Emily Wang, they are developing their technology and seeking FDA approval for its clinical use. KardioStatus aims to move away from reactive medical decision-making by using biometric-driven predictive analytics to enable proactive therapies. Chu explains that their vision is to have a better understanding of "the when" in addition to "the why" in order to achieve greater advancements in medicine. They want to address the problem of existing patient care plans being mostly reactive to current health issues. Currently, KardioStatus is focused on tackling obstructive sleep apnea (OSA), a condition characterized by interrupted breathing during sleep. By analyzing electrocardiogram data from OSA patients, they aim to predict when individuals will experience an apneic episode.

This proactive approach allows for adjustments to treatment plans and improves the quality of patients' sleep. KardioStatus is collaborating with the CRUNCH group, led by Professor George Karniadakis, who provides data collection and defines the problem, while KardioStatus develops the algorithms. The AI algorithm is trained to understand the implications of sleep apnea patient data through supervised learning. The long-term goal is to collect data through wearable technologies, such as patches or watches, eliminating the need for invasive testing. KardioStatus operates in the FDA's "Software as a Medical Device" category, as it is closely tied to clinical outcomes and can function independently of medical-grade hardware. They also aim to extend this technology to broader clinical applications, including predicting the onset of diseases using different types of input data. By engaging with a diverse group of participants, KardioStatus aims to challenge the flawed nature of existing AI data, which is often biased towards specific demographics. They are currently funded by the State of Rhode Island, have a partnership with the University, and receive external investment. In summary, KardioStatus is revolutionizing healthcare by using AI technology to analyze patient biometrics, predict medical outcomes, and enable proactive therapies. Their goal is to improve patient care by streamlining diagnosis and treatment plans, ultimately enhancing overall medical decision-making.